Zimmer Biomet leads structurally, with valuation as the clearest single gap between the two profiles. Jazz Pharmaceuticals still has the edge on growth, which keeps the comparison from looking entirely one-sided. In the market, Jazz Pharmaceuticals carries the stronger setup — intact trend against Zimmer Biomet's broken trend. That leaves a split case: the structural lead stays with Zimmer Biomet, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
Valuation still does most of the heavy lifting in this comparison. Zimmer Biomet Holdings, Inc. leads by 13 points on the overall comparison score.
These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.
The pair sits on a clearly comparable long-term path, though it is not a near-twin match.
The clearest structural overlap shows up in investment intensity and revenue stability.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Pricing shapes this comparison more than a broad operating gap.
Left means cheaper relative valuation. Higher means stronger structure.
Jazz Pharmaceuticals plc holds the stronger structural profile, but the price setup still leans toward Zimmer Biomet Holdings, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where JAZZ and ZBH each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a trailing P/E that is 2058 turns lower.
On the market side, Jazz Pharmaceuticals carries the stronger trend while Zimmer Biomet's trend has broken — the market setup does not confirm the structural advantage.
Valuation settles the comparison, while pricing and growth keep the broader setup from looking fully aligned.
Break down the JAZZ vs ZBH comparison across all dimensions with the full interactive tool.
Explore how JAZZ and ZBH each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.